UCSD researchers identify mechanism, target in NASH

Researchers from the University of California San Diego have identified a key mechanism behind the pathogenesis of non-alcoholic steatohepatitis (NASH), which could lead to a therapeutic approach and biomarkers of disease progression.

Caspases are suspected targets for NASH therapeutics. Novartis AG (NYSE:NVS; SIX:NOVN) has emricasan, a pan-caspase protease inhibitor, in Phase II testing for NASH...